[go: up one dir, main page]

CN115103683A - 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途 - Google Patents

线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途 Download PDF

Info

Publication number
CN115103683A
CN115103683A CN202180014777.1A CN202180014777A CN115103683A CN 115103683 A CN115103683 A CN 115103683A CN 202180014777 A CN202180014777 A CN 202180014777A CN 115103683 A CN115103683 A CN 115103683A
Authority
CN
China
Prior art keywords
mitochondria
tendon damage
treating
related diseases
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180014777.1A
Other languages
English (en)
Other versions
CN115103683B (zh
Inventor
郑汉中
许智凯
曾惠卿
郑安玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Chung Hsing University
Original Assignee
National Chung Hsing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Chung Hsing University filed Critical National Chung Hsing University
Priority to CN202410329264.5A priority Critical patent/CN118319951A/zh
Priority to CN202410329249.0A priority patent/CN118319950A/zh
Publication of CN115103683A publication Critical patent/CN115103683A/zh
Application granted granted Critical
Publication of CN115103683B publication Critical patent/CN115103683B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)

Abstract

线粒体在制备治疗肌腱受损相关疾病及预防由肌腱受损所引起的疾病的组合物中的用途。该线粒体具有修复受损肌腱细胞、增加肌腱细胞愈合速率的功效，能够促进肌腱受损处伤口愈合，达到修复受损肌腱的功效，进而预防因肌腱受损或发炎所导致关节疾病的发生。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202180014777.1A 2020-03-20 2021-03-19 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途 Active CN115103683B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410329264.5A CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202410329249.0A CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992546P 2020-03-20 2020-03-20
US62/992,546 2020-03-20
PCT/CN2021/081687 WO2021185342A1 (zh) 2020-03-20 2021-03-19 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410329264.5A Division CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202410329249.0A Division CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途

Publications (2)

Publication Number Publication Date
CN115103683A true CN115103683A (zh) 2022-09-23
CN115103683B CN115103683B (zh) 2024-04-09

Family

ID=77768010

Family Applications (16)

Application Number Title Priority Date Filing Date
CN202180014670.7A Active CN115135328B (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410555655.9A Pending CN118557602A (zh) 2020-03-20 2021-03-19 线粒体及富含血小板纤维蛋白用于抗发炎及/或增加胶原蛋白含量的用途
CN202411951276.8A Pending CN119876009A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202410329249.0A Pending CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途
CN202180014777.1A Active CN115103683B (zh) 2020-03-20 2021-03-19 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途
CN202311621466.9A Pending CN117379458A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410329264.5A Pending CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202311570784.7A Pending CN117357559A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202180014788.XA Active CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途
CN202180022924.XA Pending CN115335065A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202410555661.4A Pending CN118557603A (zh) 2020-03-20 2021-03-19 含有线粒体的组合物
CN202410555664.8A Pending CN118557604A (zh) 2020-03-20 2021-03-19 线粒体用于作为促进组织再生或纤维母细胞迁移的组合物的用途
CN202410414725.9A Pending CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物
CN202180022370.3A Pending CN115315248A (zh) 2020-03-20 2021-03-22 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途
CN202180022422.7A Active CN115297872B (zh) 2020-03-20 2021-03-22 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途
CN202410414731.4A Pending CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN202180014670.7A Active CN115135328B (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410555655.9A Pending CN118557602A (zh) 2020-03-20 2021-03-19 线粒体及富含血小板纤维蛋白用于抗发炎及/或增加胶原蛋白含量的用途
CN202411951276.8A Pending CN119876009A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202410329249.0A Pending CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途

Family Applications After (11)

Application Number Title Priority Date Filing Date
CN202311621466.9A Pending CN117379458A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410329264.5A Pending CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202311570784.7A Pending CN117357559A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202180014788.XA Active CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途
CN202180022924.XA Pending CN115335065A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202410555661.4A Pending CN118557603A (zh) 2020-03-20 2021-03-19 含有线粒体的组合物
CN202410555664.8A Pending CN118557604A (zh) 2020-03-20 2021-03-19 线粒体用于作为促进组织再生或纤维母细胞迁移的组合物的用途
CN202410414725.9A Pending CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物
CN202180022370.3A Pending CN115315248A (zh) 2020-03-20 2021-03-22 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途
CN202180022422.7A Active CN115297872B (zh) 2020-03-20 2021-03-22 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途
CN202410414731.4A Pending CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物

Country Status (6)

Country Link
US (6) US20230165899A1 (zh)
EP (2) EP4122474A4 (zh)
JP (2) JP7563782B2 (zh)
CN (16) CN115135328B (zh)
TW (12) TWI789724B (zh)
WO (6) WO2021185341A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
TW202506143A (zh) * 2022-05-16 2025-02-16 台灣粒線體應用技術股份有限公司 含粒線體及細胞分泌物的組合物、其用途及其製備方法
CN116478920B (zh) * 2023-05-05 2025-03-25 重庆理工大学 一种离体线粒体的体外储存方法
CN117883479A (zh) * 2023-11-02 2024-04-16 上海市第六人民医院 人源线粒体在制备治疗跟腱损伤的药物中的应用
WO2025126112A1 (en) * 2023-12-12 2025-06-19 Cells For Cells S.A. Composition enriched in mitochondria isolated from umbilical cord mesenchymal stem cells, useful in osteoarthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030647A (zh) * 2015-09-14 2015-11-11 广州赛莱拉干细胞科技股份有限公司 一种减少皱纹的制剂及其制备方法
CN105520891A (zh) * 2014-09-30 2016-04-27 李德财 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
WO2019151840A1 (ko) * 2018-02-02 2019-08-08 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586355T2 (de) * 1984-11-29 1993-01-14 Univ Minnesota Heilmittel fuer wunden.
US6100068A (en) * 1997-01-21 2000-08-08 Paik-Inje Memorial Institute For Biomedical Science Method of protein production using mitochondrial translation system
US5834418A (en) * 1996-03-20 1998-11-10 Theratechnologies, Inc. Process for the preparation of platelet growth factors extract
US7005274B1 (en) * 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
EP1711635A1 (en) * 2004-02-02 2006-10-18 Nestec S.A. Genes associated with canine osteoarthritis and related methods and compositions
WO2009002811A2 (en) * 2007-06-22 2008-12-31 Children's Medical Center Corporation Therapeutic platelet compositions and methods
US8734854B2 (en) * 2009-07-09 2014-05-27 Orogen Biosciences Inc. Process for removing growth factors from platelets
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
EP2741757B1 (en) * 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
EP2591812A1 (en) * 2011-11-14 2013-05-15 University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair
US20140024677A1 (en) * 2012-04-09 2014-01-23 Musc Foundation For Research Development Methods for inducing mitochondrial biogenesis
US10702556B2 (en) * 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
WO2014055949A1 (en) * 2012-10-04 2014-04-10 Genesys Research Institute Platelet compositions and uses thereof
WO2014121481A1 (zh) * 2013-02-07 2014-08-14 李震义 长效人重组可溶性肿瘤坏死因子α受体在制备预防和治疗慢性肝病重症肝损伤药物中的用途
US20150064715A1 (en) * 2013-08-28 2015-03-05 Musc Foundation For Research Development Urinary biomarkers of renal and mitochondrial dysfunction
TW201509425A (zh) * 2013-09-13 2015-03-16 Taichung Hospital Ministry Of Health And Welfare 以血液製備修復傷口用醫藥組合物之方法
TWI672147B (zh) * 2014-09-10 2019-09-21 台灣粒線體應用技術股份有限公司 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法
US20170290763A1 (en) * 2014-09-30 2017-10-12 Taiwan Mitochondrion Applied Technology Co., Ltd. Composition with exogenous mitochondria as active ingredients and use thereof and cell repairing method therefor
US10420798B2 (en) * 2014-12-31 2019-09-24 Taiwan Mitochondrion Applied Technology Co., Ltd Method for treating lung injury and/or diseases related to lung injury
EP3247369A4 (en) * 2015-01-15 2018-10-24 William K. Boss, Jr. Repair and rejuvenation of tissues using platelet-rich plasma
CN104546915B (zh) * 2015-02-16 2018-12-11 天晴干细胞股份有限公司 一种治疗骨性关节炎的组合物的制备方法
EP3261649A4 (en) * 2015-02-26 2018-08-15 Minovia Therapeutics Ltd. Mammalian cells enriched with functional mitochondria
US10732172B1 (en) * 2015-05-22 2020-08-04 President And Fellows Of Harvard College Methods, systems, and compositions for determining blood clot formation, and uses thereof
CA3003069A1 (en) * 2015-11-02 2017-05-11 VeriGraft AB Compositions and methods for healing wounds
WO2017095944A1 (en) * 2015-11-30 2017-06-08 Flagship Pioneering, Inc. Methods and compositions relating to chondrisomes from blood products
CN105477018A (zh) * 2015-12-07 2016-04-13 深圳爱生再生医学科技有限公司 修复皮肤溃疡的干细胞制剂及其制备方法
AU2017208013B2 (en) * 2016-01-15 2022-12-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic use of mitochondria and combined mitochondrial agents
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
TWI637748B (zh) * 2016-07-12 2018-10-11 中山醫學大學 蓮蓬萃取物用於治療及／或預防腎臟病變之用途
CN106190963A (zh) * 2016-07-13 2016-12-07 浙江大学 一种采用线粒体移植促进损伤神经元存活的方法
US20200009198A1 (en) * 2016-11-30 2020-01-09 Paean Biotechnology Inc. Pharmaceutical compostion containing mitochondria
CN106822183B (zh) * 2016-12-26 2020-04-14 中山光禾医疗科技有限公司 一种光敏富血小板血浆凝胶及其制备方法和用途
EP3600351A4 (en) * 2017-03-26 2020-11-25 Minovia Therapeutics Ltd. MITOCHONDRIAL COMPOSITIONS AND PROCESSES FOR THE TREATMENT OF THE SKIN AND HAIR
EP3624830A4 (en) * 2017-05-15 2020-12-30 Miron, Richard J. LIQUID LABEL-RICH FIBRIN AS A CARRIER SYSTEM FOR BIOMATERIALS AND BIOMOLECULES
WO2018222906A1 (en) * 2017-06-01 2018-12-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Formation of stable cartilage
US20190008896A1 (en) * 2017-07-07 2019-01-10 Richard Postrel Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions
CN107625969A (zh) * 2017-10-18 2018-01-26 南京市儿童医院 MiR‑214拮抗剂在制备用于减轻蛋白尿引起的肾小管损伤相关病症的药物中的用途
WO2019083201A2 (ko) * 2017-10-24 2019-05-02 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도
KR20190052266A (ko) * 2017-11-08 2019-05-16 원광대학교산학협력단 우르솔산을 유효성분으로 포함하는 신장 기능의 개선 또는 치료용 조성물
SG11202008839WA (en) * 2018-03-13 2020-10-29 Univ Leland Stanford Junior Transient cellular reprogramming for reversal of cell aging
WO2019183042A1 (en) * 2018-03-20 2019-09-26 Unity Biotechnology, Inc. Autologous mitochondrial extraction and expansion
MX2021000954A (es) * 2018-07-22 2021-03-31 Minovia Therapeutics Ltd Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.
JP7586811B2 (ja) * 2018-07-22 2024-11-19 ミノヴィア セラピューティクス リミテッド 腎臓疾患のミトコンドリア増強療法
JPWO2020054829A1 (ja) * 2018-09-14 2021-09-02 ルカ・サイエンス株式会社 ミトコンドリアのリンパ器官への移植およびそのための組成物
KR102128003B1 (ko) * 2018-10-31 2020-06-29 차의과학대학교 산학협력단 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물
CN110055216A (zh) * 2019-05-09 2019-07-26 张秀明 一种改善间质干细胞生物学功能的方法
CN110638833A (zh) * 2019-11-15 2020-01-03 西安圣德生物科技有限公司 促进毛发生长的组合物及其使用方法
CN110812480B (zh) * 2019-11-28 2021-04-02 中国科学院昆明动物研究所 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105520891A (zh) * 2014-09-30 2016-04-27 李德财 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN105030647A (zh) * 2015-09-14 2015-11-11 广州赛莱拉干细胞科技股份有限公司 一种减少皱纹的制剂及其制备方法
WO2019151840A1 (ko) * 2018-02-02 2019-08-08 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MIN LEE等: "Exogenous mitochondrial transplantation improves tendon regeneration via modulating apoptosis signaling", pages 420 *
刘一军等: "富血小板血浆对肌骨系统损伤修复作用的研究进展", vol. 52, no. 3, pages 461 - 465 *
汤锦波: "肌腱外科学", 上海科学技术出版社, pages: 61 - 63 *

Also Published As

Publication number Publication date
CN115297872A (zh) 2022-11-04
TW202306576A (zh) 2023-02-16
JP2024133717A (ja) 2024-10-02
CN117379458A (zh) 2024-01-12
TWI857807B (zh) 2024-10-01
US20230016499A1 (en) 2023-01-19
CN115335065A (zh) 2022-11-11
TW202135836A (zh) 2021-10-01
EP4122474A1 (en) 2023-01-25
TW202135839A (zh) 2021-10-01
TWI853788B (zh) 2024-08-21
CN115297872B (zh) 2024-03-29
TW202135838A (zh) 2021-10-01
CN115135328A (zh) 2022-09-30
TW202504624A (zh) 2025-02-01
TWI789724B (zh) 2023-01-11
TWI860566B (zh) 2024-11-01
CN119876009A (zh) 2025-04-25
WO2021185341A1 (zh) 2021-09-23
US20230042445A1 (en) 2023-02-09
CN115315248A (zh) 2022-11-08
CN115315265A (zh) 2022-11-08
WO2021185377A1 (zh) 2021-09-23
WO2021185364A1 (zh) 2021-09-23
US20230023438A1 (en) 2023-01-26
TW202438034A (zh) 2024-10-01
TWI827321B (zh) 2023-12-21
WO2021185342A1 (zh) 2021-09-23
TW202135837A (zh) 2021-10-01
CN115315265B (zh) 2024-05-31
US20230137870A1 (en) 2023-05-04
TW202308668A (zh) 2023-03-01
CN118236473A (zh) 2024-06-25
CN115103683B (zh) 2024-04-09
CN115135328B (zh) 2024-01-02
CN118319951A (zh) 2024-07-12
JP7563782B2 (ja) 2024-10-08
TWI789723B (zh) 2023-01-11
US20230023218A1 (en) 2023-01-26
TWI787761B (zh) 2022-12-21
US20230165899A1 (en) 2023-06-01
EP4122474A4 (en) 2024-05-01
JP2023518083A (ja) 2023-04-27
CN117357559A (zh) 2024-01-09
EP4122444A1 (en) 2023-01-25
CN118557602A (zh) 2024-08-30
TW202200781A (zh) 2022-01-01
WO2021185376A1 (zh) 2021-09-23
TWI796653B (zh) 2023-03-21
TWI849298B (zh) 2024-07-21
CN118252850A (zh) 2024-06-28
EP4122444A4 (en) 2024-04-17
TW202404618A (zh) 2024-02-01
WO2021185340A1 (zh) 2021-09-23
CN118557603A (zh) 2024-08-30
TWI787763B (zh) 2022-12-21
TW202135779A (zh) 2021-10-01
TW202442248A (zh) 2024-11-01
CN118557604A (zh) 2024-08-30
CN118319950A (zh) 2024-07-12

Similar Documents

Publication Publication Date Title
CN115103683A (zh) 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途
PH12021550698A1 (en) Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
BRPI0714417B8 (pt) método para fabricar uma composição de cuidado oral, de cuidado pessoal, limpadora e/ou de cuidado doméstico
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
MX389718B (es) Formulaciones y metodos de tratamiento con queratina.
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
CN112218646A (zh) 一种组合物及其应用
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
WO2008116157A3 (en) Mesenchymal stem cells and uses therefor
NO20050537L (no) Anvendelse av HMGB1 i behandlingen av vevsskade og/eller for a fremme vevsreparasjon
RS53598B1 (en) TOPICAL PREPARATIONS FOR THE CONSERVATION OR RE-ESTABLISHMENT OF MALFIN INTEGRITY
CN114502728A (zh) 改进的尿酸酶及其用于治疗高尿酸血症的方法
RS52620B (en) THE USE OF CHITOSAN FOR THE TREATMENT OF INFLAMMATORY DISEASES OF NAILS
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
WO2020128070A3 (de) Kollagenhydrolysat zur verwendung gegen hautkrankheiten und darmkrankheiten
DK1988909T3 (da) Anvendelse af polyethylenglycol til inflammationsbeslægtede topiske lidelser eller sygdomme og sårheling
CN111712573A (zh) 针对骨硬化蛋白的适体及其用途
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
CN110366427A (zh) 一种预防和治疗病理性肾组织损伤的方法
BR112021019876A2 (pt) Inibidores de pde9 para tratar anemia falciforme
JP2011505843A5 (zh)
TW200738247A (en) Method and composition for treating allergic diseases
AR119337A1 (es) Composición alimenticia para animales
MX2016013475A (es) Extracto de aloe vera para composiciones para el cuidado personal.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant